Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01981122 · ClinicalTrials.gov registry record · Phase 2
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Phase 2 study, sponsored by Dendreon.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT01981122 is a Phase 2 study that has completed, run by Dendreon. The registered enrollment target is 52 participants.
The verdict
NCT01981122, a Phase 2 study, has completed, sponsored by Dendreon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
This is a randomized, open-label study designed to assess the effects of sipuleucel-T when administered concurrently or sequentially with enzalutamide.
Interventions
- DRUG enzalutamide
- BIOLOGICAL sipuleucel-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2013-09 |
| Est. Completion | 2017-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01981122
The ClinicalTrials.gov registry entry for NCT01981122 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dendreon, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which enzalutamide is the first listed.
NCT01981122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01981122 about?
NCT01981122 is a clinical study titled "A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer". This is a randomized, open-label study designed to assess the effects of sipuleucel-T when administered concurrently or sequentially with enzalutamide.
What is the current status of trial NCT01981122?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2013-09. Estimated completion is 2017-06-30.
What interventions are being tested in trial NCT01981122?
The interventions under investigation include: enzalutamide (DRUG), sipuleucel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT01981122?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.